IO Biotech
Yahoo Finance • yesterday
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific... Full story
Yahoo Finance • last month
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors • New preclinical d... Full story
Yahoo Finance • 2 months ago
IO Biotech Reports 2024 Business Highlights
Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 p... Full story
Yahoo Finance • 2 months ago
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-... Full story
Yahoo Finance • 2 months ago
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceut... Full story
Yahoo Finance • 3 months ago
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 – NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulator... Full story
Yahoo Finance • last year
IO Biotech Announces 2023 Third Quarter Results
Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma Presented encouraging preliminary data from Pha... Full story
Yahoo Finance • last year
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of H... Full story
Yahoo Finance • last year
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
Trial expected to reach the primary endpoint of progression free survival in the second half of 2025 Per-protocol interim analysis expected in mid-2024 NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-st... Full story
Yahoo Finance • last year
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participat... Full story
Yahoo Finance • last year
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, today announced three poster p... Full story
Yahoo Finance • 2 years ago
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced encouraging preliminary data from the company’s... Full story
Yahoo Finance • 2 years ago
IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced three poster present... Full story
Yahoo Finance • 2 years ago
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancer NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-sta... Full story
Yahoo Finance • 2 years ago
10 Best New Penny Stocks to Buy Now
In this article, we will take a look at the 10 best new penny stocks to buy now. To see more such companies, go directly to 5 Best New Penny Stocks to Buy Now. The US stock market is currently in a see-saw mode as some analysts believe th... Full story
Yahoo Finance • 2 years ago
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced melanoma; trial protocol calls for an interim analysis of overall response rate (ORR) one year after... Full story
Yahoo Finance • 2 years ago
IO Biotech Announces 2022 Fourth-Quarter and Year-End Results
Enrollment in the company’s Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Pha... Full story
Yahoo Finance • 2 years ago
IO Biotech to Participate in March 2023 Investor Conferences
NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine platform, today announced participation in... Full story
Yahoo Finance • 2 years ago
IO Biotech Announces Appointment of Devin Smith as General Counsel
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today announced the appointment o... Full story
Yahoo Finance • 2 years ago
IO Biotech Provides Business Update
Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any modifications; the trial is enrolling... Full story
